BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 27085506)

  • 1. Sialic Acid Mimetics to Target the Sialic Acid-Siglec Axis.
    Büll C; Heise T; Adema GJ; Boltje TJ
    Trends Biochem Sci; 2016 Jun; 41(6):519-531. PubMed ID: 27085506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Steering Siglec-Sialic Acid Interactions on Living Cells using Bioorthogonal Chemistry.
    Büll C; Heise T; van Hilten N; Pijnenborg JF; Bloemendal VR; Gerrits L; Kers-Rebel ED; Ritschel T; den Brok MH; Adema GJ; Boltje TJ
    Angew Chem Int Ed Engl; 2017 Mar; 56(12):3309-3313. PubMed ID: 28194834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression profiling of immune inhibitory Siglecs and their ligands in patients with glioma.
    Santegoets KCM; Gielen PR; Büll C; Schulte BM; Kers-Rebel ED; Küsters B; Bossman SAJFH; Ter Laan M; Wesseling P; Adema GJ
    Cancer Immunol Immunother; 2019 Jun; 68(6):937-949. PubMed ID: 30953118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Murine Red Blood Cells Lack Ligands for B Cell Siglecs, Allowing Strong Activation by Erythrocyte Surface Antigens.
    Spiller F; Nycholat CM; Kikuchi C; Paulson JC; Macauley MS
    J Immunol; 2018 Feb; 200(3):949-956. PubMed ID: 29288201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and expression of 3 siglecs-like in Oreochromis niloticus neutrophil, and their interaction with group B streptococcal sialylated capsular polysaccharides.
    Dong J; Wei Y; Ye X; Sun C; Tian Y; Lu M; Du J; Chen Z
    Mol Immunol; 2016 May; 73():158-69. PubMed ID: 26847490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B Cell Siglecs-News on Signaling and Its Interplay With Ligand Binding.
    Meyer SJ; Linder AT; Brandl C; Nitschke L
    Front Immunol; 2018; 9():2820. PubMed ID: 30559744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sugar Free: Novel Immunotherapeutic Approaches Targeting Siglecs and Sialic Acids to Enhance Natural Killer Cell Cytotoxicity Against Cancer.
    Daly J; Carlsten M; O'Dwyer M
    Front Immunol; 2019; 10():1047. PubMed ID: 31143186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Siglec and anti-Siglec therapies.
    Murugesan G; Weigle B; Crocker PR
    Curr Opin Chem Biol; 2021 Jun; 62():34-42. PubMed ID: 33607404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Siglecs: A journey through the evolution of sialic acid-binding immunoglobulin-type lectins.
    Bornhöfft KF; Goldammer T; Rebl A; Galuska SP
    Dev Comp Immunol; 2018 Sep; 86():219-231. PubMed ID: 29751010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of Immune Tolerance via Siglec-Sialic Acid Interactions.
    Lübbers J; Rodríguez E; van Kooyk Y
    Front Immunol; 2018; 9():2807. PubMed ID: 30581432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deacetylated sialic acids modulates immune mediated cytotoxicity via the sialic acid-Siglec pathway.
    Grabenstein S; Barnard KN; Anim M; Armoo A; Weichert WS; Bertozzi CR; Parrish CR; Willand-Charnley R
    Glycobiology; 2021 Nov; 31(10):1279-1294. PubMed ID: 34192335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Probing the cis interactions of the inhibitory receptor Siglec-7 with alpha2,8-disialylated ligands on natural killer cells and other leukocytes using glycan-specific antibodies and by analysis of alpha2,8-sialyltransferase gene expression.
    Avril T; North SJ; Haslam SM; Willison HJ; Crocker PR
    J Leukoc Biol; 2006 Oct; 80(4):787-96. PubMed ID: 16857734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sialic Acid-Siglec Axis in Human Immune Regulation, Involvement in Autoimmunity and Cancer and Potential Therapeutic Treatments.
    Gianchecchi E; Arena A; Fierabracci A
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The sialoglycan-Siglec glyco-immune checkpoint - a target for improving innate and adaptive anti-cancer immunity.
    Bärenwaldt A; Läubli H
    Expert Opin Ther Targets; 2019 Oct; 23(10):839-853. PubMed ID: 31524529
    [No Abstract]   [Full Text] [Related]  

  • 15. Targeting myeloid cells for cancer immunotherapy: Siglec-7/9/10/15 and their ligands.
    Boelaars K; van Kooyk Y
    Trends Cancer; 2024 Mar; 10(3):230-241. PubMed ID: 38160071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Possible Influences of Endogenous and Exogenous Ligands on the Evolution of Human Siglecs.
    Angata T
    Front Immunol; 2018; 9():2885. PubMed ID: 30564250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A versatile soluble siglec scaffold for sensitive and quantitative detection of glycan ligands.
    Rodrigues E; Jung J; Park H; Loo C; Soukhtehzari S; Kitova EN; Mozaneh F; Daskhan G; Schmidt EN; Aghanya V; Sarkar S; Streith L; St Laurent CD; Nguyen L; Julien JP; West LJ; Williams KC; Klassen JS; Macauley MS
    Nat Commun; 2020 Oct; 11(1):5091. PubMed ID: 33037195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation of Recombinant Siglecs and Identification of Their Ligands.
    Chang LY; Low PY; Sridharan D; Gerlovin K; Angata T
    Methods Mol Biol; 2020; 2132():85-98. PubMed ID: 32306317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of sialic acid diversity in cancer- and non-cancer related CA125 antigen using sialic acid-binding Ig-like lectins (Siglecs).
    Mitic N; Milutinovic B; Jankovic M
    Dis Markers; 2012; 32(3):187-94. PubMed ID: 22377735
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Yang J; Ma W; Wu Y; Zhou H; Song S; Cao Y; Wang C; Liu X; Ren J; Duan J; Pei Z; Jin C
    Microbiol Spectr; 2021 Dec; 9(3):e0039921. PubMed ID: 34878295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.